Labcorp Holdings’ $1.36 Billion Cash Flow Path — The Earnings Engine Is Strengthening!

Labcorp Holdings reported its financial results for the second quarter of 2026, demonstrating modest growth and operational improvements amid a dynamic healthcare testing environment. The company’s consolidated revenue increased by approximately 6% to $3.7 billion compared to the prior year, driven by both organic growth and contributions from acquisitions. Adjusted earnings per share (EPS) rose nearly 15% to $4.99, supported by margin expansion and operating efficiencies. Free cash flow totaled $314 million for the quarter, a decline from $543 million in the previous year mainly due to working capital timing and increased capital expenditures. Labcorp’s adjusted operating margin improved by 70 basis points to 15.8%, with both the Diagnostics and Biopharma Laboratory Services (BLS) segments contributing to the margin expansion. In the Diagnostics segment, revenue grew 5.5% to $2.9 billion, reflecting organic growth of 3.6%, comprising 1.8% volume growth and a 1.